Compare and contrast diagnostic test Vs screening test
Reading File
Finding Sources
Searching the Web
diagnostic test vs screening test comparison criteria sensitivity specificity
Finding Sources
Reading Web Page
https://www.healthknowledge.org.uk/public-health-textbook/di…
Reading File
Reading File
Excellent - I now have rich content from both Park's Textbook of Preventive and Social Medicine and Creasy & Resnik's Maternal-Fetal Medicine. Let me compile the full detailed answer.
Diagnostic Test vs. Screening Test: Compare and Contrast
Definitions
Screening test - "the search for unrecognized disease or defect by means of rapidly applied tests, examinations or other procedures in apparently healthy individuals." - Park's Textbook of Preventive and Social Medicine
Diagnostic test - A test used to establish the presence or absence of disease as a basis for treatment decisions in symptomatic individuals, or in those who have screened positive. The diagnosis is "the sum of all evidence" and is modified in light of new findings. - Park's Textbook
Detailed Comparison Table
| Feature | Screening Test | Diagnostic Test |
|---|---|---|
| Purpose | Detect potential disease indicators; presumptive identification of unrecognized disease | Establish definitive presence/absence of disease; basis for treatment |
| Target population | Large groups of apparently healthy, asymptomatic individuals | Symptomatic individuals, or asymptomatic individuals with a positive screening result |
| Application | Applied to groups | Applied to single patients; all possible diseases are considered |
| Result interpretation | Positive result = suspicion of disease, warrants further confirmation - NOT a definitive diagnosis | Positive result = definitive diagnosis; basis for immediate management |
| Finality | Test results are preliminary; always followed by further workup if positive | Diagnosis is not static but is modified in light of new evidence; still the most definitive available answer |
| Basis of result | Based on one criterion or cut-off point | Based on evaluation of many factors: symptoms, signs, lab findings, imaging |
| Accuracy | Less accurate; designed to cast a wide net | More accurate; designed to give a precise answer |
| Cost | Cheap; designed to be applied to large populations | Higher cost is justified by the need to establish a definitive diagnosis |
| Complexity/Invasiveness | Simple, rapid, acceptable to patients and staff | May be invasive or complex, but justified by clinical necessity |
| Physician involvement | Technicians can administer; physician interprets | Usually requires physician involvement throughout |
| Statistical priority | High sensitivity - minimizes false negatives (must not miss cases) | High specificity - minimizes false positives (must confirm true disease) |
| Positive threshold | Threshold set toward high sensitivity; accepts more false positives | Threshold set toward high specificity; accepts fewer false negatives at the cost of not missing true cases |
| Follow-up required | Yes - all positives must be referred for diagnostic workup | No further confirmation usually needed; leads directly to treatment |
| Examples | Mammography, PAP smear, blood pressure check, HbA1c in a health camp, HIV rapid test | Biopsy, culture & sensitivity, coronary angiography, amniocentesis, OGTT |
Key Conceptual Differences
1. Population vs. Individual
Screening is a population-level public health tool. It is applied en masse, often as part of organized programs. Diagnostic testing is an individualized clinical tool applied to one patient with a clinical question.
2. Sensitivity vs. Specificity Priority
- Screening prioritizes sensitivity: We want to catch every possible case. Missing a case (false negative) is the greater harm. Higher false-positive rate is acceptable because the cost is only further investigation.
- Diagnostic testing prioritizes specificity: A false positive could lead to unnecessary treatment, psychological harm, or invasive procedures. We want to confirm disease with certainty.
A useful mnemonic: SnOUT / SpIN
- SnOUT: A highly Sensitive test, when negative, rules OUT disease (good for screening).
- SpIN: A highly Specific test, when positive, rules IN disease (good for diagnosis).
3. The Two-Stage Cascade
In practice, screening and diagnosis are not alternatives - they form a sequential cascade:
Screening (wide net, asymptomatic population) → Positive screen → Diagnostic workup (confirms or refutes) → Treatment
Example from Creasy & Resnik: A family history (screening) leads to targeted ultrasound (may be diagnostic) and eventually to amniocentesis (definitive diagnostic test) - Park's Textbook of Preventive and Social Medicine & Creasy & Resnik's Maternal-Fetal Medicine.
4. Criteria for a Good Screening Program (Wilson & Jungner)
A screening test is only justified when (healthknowledge.org.uk):
- The condition has a significant health burden
- Effective early treatment is available (no point screening if there is nothing to offer)
- The test is valid, reliable, sensitive, and specific
- It is inexpensive, easy to perform, safe, and acceptable
- The program is cost-effective overall
A classic counter-example: Cytomegalovirus causes significant fetal disease, but because there is no effective intervention, screening is not justified despite the disease burden. - Creasy & Resnik's Maternal-Fetal Medicine
Predictive Values - The Practical Overlap
Both types of tests are evaluated using:
| Measure | Definition |
|---|---|
| Sensitivity | True positive rate - % of diseased who test positive |
| Specificity | True negative rate - % of non-diseased who test negative |
| PPV | Probability that a positive test = true disease |
| NPV | Probability that a negative test = true no disease |
PPV and NPV differ crucially from sensitivity/specificity: they depend on disease prevalence. In a low-prevalence screening population, even a highly sensitive test will yield many false positives - this is why screening positives always need diagnostic confirmation.
Summary
| Screening | Diagnostic | |
|---|---|---|
| Who? | Healthy population | Symptomatic/screen-positive individual |
| Goal? | Find hidden cases early | Confirm or rule out disease |
| Accuracy? | Less (acceptable) | High (required) |
| Priority stat? | Sensitivity | Specificity |
| Outcome? | Presumptive suspicion | Definitive diagnosis |
| Cost? | Low | Higher justified |
| Final? | No - needs follow-up | Yes - guides treatment |
In summary, screening and diagnostic tests are complementary tools: screening casts a wide, inexpensive net over healthy populations to flag possible disease, while diagnostic testing uses greater precision, cost, and often invasiveness to confirm or exclude that disease in flagged individuals. Neither replaces the other.
What are Wilson's criteria for evaluating screening programs?
Finding Sources
Searching the Web
Wilson Jungner 10 criteria screening programs 1968 WHO
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading Web Page
https://niercheck.nl/wp-content/uploads/2019/06/Wilson-Jungn…
Reading File
Reading File
Reading File
I now have comprehensive content from Park's Textbook, Emery's Medical Genetics, and Tietz Textbook of Laboratory Medicine. Here is the complete answer:
Wilson and Jungner's Criteria for Evaluating Screening Programs
Wilson and Jungner published these 10 classic principles in 1968 for the WHO (Public Health Papers No. 34: Principles and Practice of Screening for Disease). They remain the foundational framework for deciding whether a screening program is justified and are referenced in guidelines to this day. - Tietz Textbook of Laboratory Medicine, 7th Edition
Park's Textbook of Preventive and Social Medicine organizes these criteria into two domains: the disease and the test.
Domain 1: Criteria Related to the Disease
1. The condition should be an important health problem
The disease must have significant prevalence or cause serious morbidity/mortality in the target population. Screening a rare or trivial disease wastes resources.
2. There should be a recognizable latent or early asymptomatic stage
Without a detectable pre-symptomatic window, screening cannot offer any advantage over waiting for symptoms to appear. This is the whole rationale of early detection.
3. The natural history of the condition must be adequately understood
We must know how the disease progresses from latent to declared disease - specifically, at what point the process becomes irreversible. Without this knowledge, we cannot define the optimal window for intervention.
4. There must be a test that can detect the disease before onset of signs and symptoms
This follows directly from criterion 3 - a practical tool must exist to identify disease in the pre-symptomatic window.
5. Facilities must be available for confirmation of diagnosis (and treatment)
A positive screen must be followed by proper diagnostic workup. Screening without the infrastructure to investigate positive results is unethical and harmful.
6. There must be an effective treatment
No benefit accrues from detecting disease early if nothing can be done about it. Classic example: cytomegalovirus (CMV) causes significant fetal harm, but the absence of effective treatment makes mass screening unjustifiable.
7. There should be an agreed-upon policy about whom to treat
For conditions with borderline values (e.g., borderline diabetes, lower ranges of hypertension), there must be consensus on who constitutes a "case" requiring treatment versus surveillance.
8. There must be good evidence that early detection and treatment reduces morbidity and mortality
Detection alone is not enough. There must be proof that intervening early actually improves outcomes compared to treating at symptom onset.
9. Expected benefits must exceed the risks and costs
The number of lives saved (and suffering prevented) must outweigh the physical risks, psychological harms (anxiety from false positives), and financial costs of the program.
Domain 2: Criteria Related to the Screening Test
10. The test must satisfy the criteria of:
| Property | Meaning |
|---|---|
| Acceptability | Must be acceptable to the target population - painful, embarrassing, or invasive tests (e.g., rectal exam in mass campaigns) will yield poor participation and defeat the program |
| Repeatability (Reliability) | Must give consistent results when repeated on the same individual under the same conditions - includes minimizing intra-observer and inter-observer variation |
| Validity (Accuracy) | Must accurately distinguish those with from those without disease - measured by sensitivity and specificity |
| Simplicity | Should be easy to administer, ideally by non-physician technicians |
| Safety | Must pose minimal physical risk to the large number of healthy individuals being tested |
| Rapidity | Must be quick to apply at scale |
| Yield | Must detect a meaningful number of previously unrecognized cases |
| Low cost | Must be cheap enough to justify application to large populations |
- Park's Textbook of Preventive and Social Medicine; Emery's Elements of Medical Genetics and Genomics
The Classic 10-Point Summary (Wilson & Jungner, 1968)
| # | Criterion | Category |
|---|---|---|
| 1 | Condition is an important health problem | Disease |
| 2 | Accepted treatment available for recognized disease | Disease |
| 3 | Facilities for diagnosis and treatment available | Disease |
| 4 | Recognizable latent or early symptomatic stage | Disease |
| 5 | Suitable test or examination available | Test |
| 6 | Test acceptable to the population | Test |
| 7 | Natural history adequately understood | Disease |
| 8 | Agreed-upon policy on whom to treat | Disease |
| 9 | Cost economically balanced against benefit | Program |
| 10 | Case-finding is a continuing process (not a once-off event) | Program |
Practical Application: Does Prostate Cancer Screening Pass?
The Tietz Textbook applies the WHO/Wilson criteria directly to prostate cancer (PSA screening) vs. choriocarcinoma screening and finds:
| WHO Criterion | Choriocarcinoma (UK) | Prostate Cancer (PSA) |
|---|---|---|
| Early intervention more beneficial | YES - chemotherapy highly desirable early | UNCERTAIN - benefit only in localized disease; watchful waiting equally appropriate in some |
| Effective treatment available | YES - chemotherapy highly effective | PARTIAL - radical prostatectomy curative only if confined |
| Adequate facilities | YES - specialist centres exist | Requires significant additional diagnostic resources |
| Agreed policy on whom to treat | YES | PARTIAL - no consensus on how to select beneficiaries |
| Benefit outweighs harm | YES - life-saving | NO - incontinence, impotence, psychological anxiety from false positives |
| Cost-effective | YES - low cost vs. lives saved | UNCLEAR - costs likely considerable |
This illustrates why choriocarcinoma screening is well-established while PSA screening remains controversial. - Tietz Textbook of Laboratory Medicine, 7th Edition
Modern Updates
The original 1968 criteria have been revisited as medicine evolved - particularly for genomic/newborn screening. A 2018 systematic review (Dobrow et al., PMC5893317) synthesized updated consolidated principles, noting that the Wilson-Jungner criteria remain the "de facto starting point" but need supplementation for modern contexts like genetic screening, where actionability and equity have become additional key considerations.
This is a shared conversation. Sign in to Orris to start your own chat.